Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 13.36B P/E 59.48 EPS this Y 3.60% Ern Qtrly Grth 97.80%
Income 263M Forward P/E 14.30 EPS next Y 18.60% 50D Avg Chg -1.00%
Sales 5.55B PEG 1.27 EPS past 5Y 5.17% 200D Avg Chg 6.00%
Dividend 3.00% Price/Book 2.46 EPS next 5Y 11.30% 52W High Chg -11.00%
Recommedations 1.00 Quick Ratio 0.67 Shares Outstanding 874.35M 52W Low Chg 38.00%
Insider Own 0.19% ROA 4.27% Shares Float 862.75M Beta 0.51
Inst Own 56.20% ROE 5.02% Shares Shorted/Prior -/- Price 14.87
Gross Margin 70.14% Profit Margin 4.74% Avg. Volume 2,337 Target Price -
Oper. Margin 14.46% Earnings Date Aug 1 Volume 13 Change 0.00%
About SMITH & NEPHEW

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

SMITH & NEPHEW News
04/22/24 With 83% ownership of the shares, Smith & Nephew plc (LON:SN.) is heavily dominated by institutional owners
04/18/24 Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s role in pressure injury prevention
04/08/24 Smith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in Australia
04/08/24 Here’s Why You Should Invest in Smith & Nephew plc (SNN)
10:13 AM Smith+Nephew’s PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)
04/03/24 Investors five-year losses continue as Smith & Nephew (LON:SN.) dips a further 5.6% this week, earnings continue to decline
04/01/24 Smith+Nephew introduces the RENASYS™ EDGE Negative Pressure Wound Therapy System – an exciting new option in home-based care for patients living with chronic wounds
04/01/24 Smith & Nephew PLC's Dividend Analysis
03/25/24 Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner
03/18/24 Some Investors May Be Worried About Smith & Nephew's (LON:SN.) Returns On Capital
03/13/24 7 Robotic Surgery Stocks to Buy for the Future of Healthcare
03/01/24 Smith & Nephew plc Just Missed EPS By 38%: Here's What Analysts Think Will Happen Next
02/28/24 Smith & Nephew plc (NYSE:SNN) Q4 2023 Earnings Call Transcript
02/28/24 Smith+Nephew and U.S. Army Institute of Surgical Research to engage in Master Cooperative Research and Development Agreement
02/27/24 Basic Materials Roundup: Market Talk
02/27/24 Health Care Roundup: Market Talk
02/21/24 Are Investors Undervaluing Smith & Nephew SNATS (SNN) Right Now?
02/14/24 Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
02/13/24 Smith+Nephew announces commercial launch of its AETOS™ Shoulder System for anatomic and reverse shoulder replacement at AAOS 2024 Annual Meeting
02/12/24 Smith+Nephew to showcase leading, innovative AI-driven robotic-assisted solutions for personalized orthopaedic surgery at AAOS 2024 Annual Meeting